Improving Potency, Selectivity, and Water Solubility of Adenosine A1Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinediones

Authors:

Abstract
The structure–activity relationships of xanthine derivatives related to the adenosine A1receptor antagonists 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX) and 1,3‐dipropyl‐8‐(3‐noradamantyl)xanthine (KW3902) were investigated by focusing on variations of the 3‐substituent. Aromatic residues were well tolerated by the A1receptor in that position. A moderate effect of stereochemistry was found for the 3‐(1‐phenylethyl)‐substituted analogue of DPCPX (S>R) at A1and A3receptors, whereas the opposite stereoselectivity was observed at the A2receptor subtypes. A 3‐hydroxypropyl substituent was found to be optimal for high A1affinity and selectivity. The most potent compound of the present series was 1‐butyl‐3‐(3‐hydroxypropyl)‐8‐(3‐noradamantyl)xanthine (10 c), which exhibits aKivalue of 0.124 nMat rat, and 0.7 nMat human adenosine A1receptors, combined with high selectivity (≫200‐fold) versus the other receptor subtypes. The similarly potent 8‐cyclopentyl‐3‐(3‐hydroxypropyl)‐1‐propylxanthine was converted into a water‐soluble phosphate prodrug, which may become a useful pharmacological tool for in vivo studies. 8‐Alkyl‐2‐(3‐noradamantyl)pyrimido[1,2,3‐cd]purine‐8,10‐diones, which can be envisaged as xanthine analogues with a fixed 3‐propyl substituent, were identified as a new class of potent, selective adenosine A1receptor antagonists. For example, compound14(8‐butyl‐substituted) exhibits aKivalue of 13.8 nMat human A1receptors. A selection of the most potent compounds was investigated in [35S]GTPγS binding assays and showed inverse agonistic activity. Their efficacy was generally lower than that of the full inverse agonist DPCPX, and depended on subtle structural changes. Some of the new compounds belong to the most potent and selective A1antagonists described to date.

This publication has 39 references indexed in Scilit: